WO/2014/117228 TEA FERMENTATION METHOD AND DEVICE FOR IMPLEMENTING SAME||WO||07.08.2014|
||PCT/AZ2013/000002||PASHAYEV, Arif Mirjalal||PASHAYEV, Arif Mirjalal|
The invention relates to the food industry, to medicine and to agriculture, and specifically to a tea fermentation process for use in the processing of cultivated and wild plant raw material. The fermentation method includes subjecting the raw material to an ozone-air mixture, having an ozone concentration of 0.03-0.04 ppm (0.06-0.08 mg/m), at a relative humidity of 95-98% and a temperature of 22-24°С for a period of 40-50 minutes under conditions of operational control over the condition of the product. The device for implementing the fermentation method comprises coaxially arranged electrodes connected to a high voltage source and, between said electrodes, a dielectric barrier in the form of a tubular ozonizer, flexible tubing for inputting the ozone-air mixture, and a humidifying temperature controller which provides for the relative humidity and temperature in the fermentation chamber. Subjecting the raw material to the ozone-air mixture results in an increase in fermentation process output and in the qualitative indicators of the final product.
WO/2014/094844 LOCALIZED DISINFECTION SYSTEM FOR LARGE WATER BODIES||WO||26.06.2014|
||PCT/EP2012/076170||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN, Fernando Benjamin|
The present disclosure relates to a method for controlling the microbiological properties of a portion of water within a large body of water by treating such zone with chemical agents, according to the temperature of the water, its salinity, its dilution power and the diffusion of chemicals within the large water body.
WO/2014/071231 TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY||WO||08.05.2014|
||PCT/US2013/068132||PHARMACYCLICS, INC.||BUGGY, Joseph, J.|
Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
WO/2014/071339 BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION||WO||08.05.2014|
||PCT/US2013/068386||PALATIN TECHNOLOGIES, INC.||SPANA, Carl|
Use of a subcutaneously administered dose of between about 1,0 mg and 175 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
WO/2014/063868 GALACTAGOGUE COMPOSITIONS BASED ON PHOSPHATIDYLSERINE||WO||01.05.2014|
||PCT/EP2013/069466||VELLEJA RESEARCH S.R.L.||DI PIERRO, Francesco|
The present invention relates to galactagogue compositions based on phosphatidylserine for use in the treatment of hypogalactia.
WO/2014/061031 2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS||WO||24.04.2014|
||PCT/IN2013/000627||CADILA HEALTHCARE LIMITED||DESAI, Ranjit, C.|
The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
WO/2014/057080 N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS||WO||17.04.2014|
||PCT/EP2013/071253||H. LUNDBECK A/S||KILBURN, John Paul|
The present invention is directed to N-(2-(cyclic amine)ethyl)benzamide derivatives of formula (I), as P2X7 inhibitors, pharmaceutical compositions comprising said compounds and uses of the compounds to treat pain, inflammation, neurological disorders, or neuropsychiatric disorders.
||PCT/EP2013/071247||H. LUNDBECK A/S||KILBURN, John Paul|
The present application relates to compounds of formula (I), wherein R1 to R5 are as defined in claim 1, a pharmaceutical composition thereof and said compounds for use in the treatment of diseases related with the activity of P2X7 receptor.
WO/2014/059422 NOVEL PROCESS FOR MAKING COMPOUNDS FOR USE IN THE TREATMENT OF CANCER||WO||17.04.2014|
||PCT/US2013/064866||EXELIXIS, INC.||NAGANATHAN, Sriram|
Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
WO/2014/053891 METHOD FOR THE DETOXIFICATION OF GLUTEN PROTEINS FROM GRAINS OF CEREALS||WO||10.04.2014|
||PCT/IB2013/000797||UNIVERSITA' DEGLI STUDI DI FOGGIA||DI LUCCIA, Aldo|
The method allows to obtain gluten detoxified flours suitable for the preparation of bakery products and pasta made from wheat. With the use of the method gluten proteins undergo structural changes that do not activate in patients suffering from celiac disease, the cascade of inflammatory cytokines. Such structural changes, in addition, do not affect the technical properties of the flours that form the dough, therefore allowing the preparation of detoxified products, similar in taste and appearance to those commonly used in Mediterranean diet and which are intended not only for the people who suffer from intolerance to gluten, but for the whole population. The widespread use of such detoxified products in large part of the population has the purpose, in a totally innovative way, to provoke the reduction of gluten's effects in people's health and therefore to the decrease in the incidence of celiac disease.